Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Nkarta, Inc. (NKTX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/10/2023 |
SC 13G/A
| WASATCH ADVISORS LP reports a 3.8% stake in Nkarta Inc. |
| 08/23/2023 |
4
| Shook David (Chief Medical Officer) has filed a Form 4 on Nkarta, Inc.|
Txns:
| Sold 1,331 shares
@ $1.83, valued at
$2.4k
|
|
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 07/05/2023 |
4
| Levin Alyssa (See Remarks) has filed a Form 4 on Nkarta, Inc.|
Txns:
| Granted 442,400 options to buy
@ $2.19, valued at
$968.9k
|
|
| 07/05/2023 |
3
| Levin Alyssa (See Remarks) has filed a Form 3 on Nkarta, Inc. |
| 07/05/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/05/2023 |
4
| Shook David (Chief Medical Officer) has filed a Form 4 on Nkarta, Inc.|
Txns:
| Granted 208,000 options to buy
@ $2.19, valued at
$455.5k
|
|
| 06/09/2023 |
4
| George Simeon (Director) has filed a Form 4 on Nkarta, Inc.|
Txns:
| Granted 22,500 options to buy
@ $4.86, valued at
$109.4k
|
|
| 06/09/2023 |
4
| Behbahani Ali (Director) has filed a Form 4 on Nkarta, Inc.|
Txns:
| Granted 22,500 options to buy
@ $4.86, valued at
$109.4k
|
|
| 06/09/2023 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on Nkarta, Inc.|
Txns:
| Granted 22,500 options to buy
@ $4.86, valued at
$109.4k
|
|
| 06/09/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 06/09/2023 |
4
| Thedinga Angela (Director) has filed a Form 4 on Nkarta, Inc.|
Txns:
| Granted 22,500 options to buy
@ $4.86, valued at
$109.4k
|
|
| 06/09/2023 |
4
| PATTERSON LEONE D (Director) has filed a Form 4 on Nkarta, Inc.|
Txns:
| Granted 22,500 options to buy
@ $4.86, valued at
$109.4k
|
|
| 06/09/2023 |
4
| Dybbs Michael (Director) has filed a Form 4 on Nkarta, Inc.|
Txns:
| Granted 22,500 options to buy
@ $4.86, valued at
$109.4k
|
|
| 06/09/2023 |
4
| Azzam Fouad Oscar (Director) has filed a Form 4 on Nkarta, Inc.|
Txns:
| Granted 22,500 options to buy
@ $4.86, valued at
$109.4k
|
|
| 06/09/2023 |
4
| Scheiner Zachary (Director) has filed a Form 4 on Nkarta, Inc.|
Txns:
| Granted 22,500 options to buy
@ $4.86, valued at
$109.4k
|
|
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights • Clinical updates on track for NKX101 in second quarter of 2023 at a company-hosted event and NKX019 in second half of 2023 • Cash and cash equivalents of $332.1 million on March 31, 2023 • Cash runway anticipated to fund operations into 2025 SOUTH SAN FRANCISCO, Calif., May 11, 2023 -- Nkarta, Inc. , a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies, today reported financial results for the first quarter ended March 31, 2023. “Nkarta remains focused on the potential of donor-derived CAR NK cell products to broaden access to the transformative power of cell therapy for patients,” said Paul J. Hastings, CEO and President of Nkarta. &#x..." |
|
| 05/10/2023 |
SC 13G/A
| WASATCH ADVISORS LP reports a 10.1% stake in Nkarta Inc. |
| 05/08/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/24/2023 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 04/24/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/24/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/24/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/14/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/17/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 03/16/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/16/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13D/A
| Samsara BioCapital, L.P. reports a 5.9% stake in Nkarta, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/09/2023 |
SC 13G
| WASATCH ADVISORS INC reports a 5.6% stake in Nkarta Inc. |
|
|
|